Enhanced GS® CHO Vector Technology for Improved Expression Control of Biotherapeutic Proteins

Many of today’s expression platforms for recombinant protein production have been optimised for the expression of monoclonal antibodies, often with the platform fundamentals originating from the 1990s. However, as new modalities increase in prevalence, particularly multichain asymmetric antibodies and bispecifics, there is a demand for improvements to vector design to enable optimal expression and production of these diverse formats. In this webinar, Lonza's Dr. Peter O'Callaghan presents on how Lonza is developing enhanced GS® vector technology to enable better control of expression in CHOK1SV GS-KO® cells, enhance titres and improve expression stability for a range of biotherapeutic formats.